|
US3933797A
(en)
|
1972-02-22 |
1976-01-20 |
Pfizer Inc. |
6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS
|
|
BE794886A
(fr)
|
1972-02-22 |
1973-08-02 |
Pfizer |
Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
|
|
US3972872A
(en)
|
1974-09-23 |
1976-08-03 |
Pfizer Inc. |
6-[α-(ω-Guanidinoalkanoylamido)acylamido]penicillanic acids
|
|
ATE70048T1
(de)
|
1986-09-10 |
1991-12-15 |
Syntex Inc |
Selektive amidinierung von diaminen.
|
|
US5321030A
(en)
|
1989-02-14 |
1994-06-14 |
Amira, Inc. |
Creatine analogs having antiviral activity
|
|
US5676978A
(en)
|
1989-02-14 |
1997-10-14 |
Amira, Inc. |
Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
|
|
EP0458901B1
(en)
|
1989-02-14 |
1997-12-17 |
Massachusetts Institute Of Technology |
Inhibiting transformation of cells having elevated purine metabolic enzyme activity
|
|
US5324731A
(en)
|
1989-02-14 |
1994-06-28 |
Amira, Inc. |
Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
|
|
CA2028593C
(en)
|
1989-10-31 |
2007-08-21 |
Douglas R. Brandt |
Stabilized enzyme compositions
|
|
AU7316591A
(en)
*
|
1990-02-28 |
1991-09-18 |
Upjohn Company, The |
Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
|
|
EP0601001B1
(en)
*
|
1991-08-26 |
1997-04-16 |
PHARMACIA & UPJOHN COMPANY |
Liquid food product containing 3-guanidinopropionic acid
|
|
WO1994016687A1
(en)
|
1993-01-28 |
1994-08-04 |
The Trustees Of The University Of Pennsylvania |
Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
|
|
DE4334639A1
(de)
|
1993-10-11 |
1995-04-13 |
Inst Neue Mat Gemein Gmbh |
Verfahren zur Herstellung von TiN-Sinterkörpern und -Schichten
|
|
US5994577A
(en)
|
1994-11-23 |
1999-11-30 |
Larsen; Scott D. |
Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
|
|
PT793646E
(pt)
|
1994-11-23 |
2002-03-28 |
Biovitrum Ab |
Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
|
|
JP3745439B2
(ja)
|
1995-07-06 |
2006-02-15 |
花王株式会社 |
皮膚外用剤
|
|
EP0854712B1
(en)
|
1995-10-11 |
2003-05-07 |
Avicena Group, Inc. |
Use of creatine analogues for the treatment of disorders of glucose metabolism
|
|
TW453881B
(en)
|
1995-10-16 |
2001-09-11 |
Kao Corp |
Cosmetic composition comprising amide derivatives
|
|
US5998457A
(en)
|
1995-10-26 |
1999-12-07 |
Avicena Group, Inc. |
Creatine analogues for treatment of obesity
|
|
AU3117497A
(en)
|
1996-05-21 |
1997-12-09 |
Pharmacia & Upjohn Company |
Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus
|
|
JP4317599B2
(ja)
|
1996-06-26 |
2009-08-19 |
武田薬品工業株式会社 |
徐放性製剤
|
|
AR019727A1
(es)
|
1998-06-30 |
2002-03-13 |
Takeda Chemical Industries Ltd |
Composicion farmaceutica
|
|
US6605115B1
(en)
|
1999-06-05 |
2003-08-12 |
Board Of Trustees Of The Leland Stanford Junior University |
Method and composition for inhibiting cardiovascular cell proliferation
|
|
EP1656945A1
(en)
|
1999-06-05 |
2006-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Pharmaceutical composition comprising oligoarginine
|
|
US6242491B1
(en)
|
1999-06-25 |
2001-06-05 |
Rima Kaddurah-Daouk |
Use of creatine or creatine compounds for skin preservation
|
|
US20020082448A1
(en)
|
1999-11-08 |
2002-06-27 |
The Upjohn Company |
Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
|
|
US6518299B1
(en)
|
2000-10-20 |
2003-02-11 |
Biocryst Pharmaceuticals, Inc. |
Substituted pyrrolidine compounds useful as neuraminidase inhibitors
|
|
CA2456964A1
(en)
|
2001-08-08 |
2003-02-20 |
Merck & Co., Inc. |
Melanin-concentrating hormone antagonists
|
|
WO2003039449A2
(en)
|
2001-11-07 |
2003-05-15 |
Medical Research Council |
Modulation of dopaminergic neurons
|
|
CA2473229A1
(en)
|
2002-01-09 |
2003-07-24 |
Merck & Co., Inc. |
Selective melanin-concentrating hormone type -1 receptor agonists
|
|
EP1567180A4
(en)
|
2002-06-04 |
2010-03-10 |
Avicena Group Inc |
METHOD FOR THE TREATMENT OF COGNITIVE DYSFUNCTION BY MODULATING THE CHANGE OF ENERGY REPLACEMENT IN THE BRAIN
|
|
US20120245211A1
(en)
|
2002-06-04 |
2012-09-27 |
Children's Hospital Medical Center |
Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism
|
|
GB0302882D0
(en)
|
2003-02-07 |
2003-03-12 |
Univ Cardiff |
Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
|
|
EP1746099A1
(en)
|
2004-12-23 |
2007-01-24 |
DeveloGen Aktiengesellschaft |
Mnk1 or Mnk2 inhibitors
|
|
JP4865251B2
(ja)
|
2005-05-09 |
2012-02-01 |
株式会社 資生堂 |
不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物
|
|
US20090297656A1
(en)
|
2005-08-02 |
2009-12-03 |
Thomas Gastner |
Liquid Formulation Based On a Guanidinoacetic Acid Component
|
|
WO2008054544A2
(en)
|
2006-05-22 |
2008-05-08 |
Immune Disease Institute, Inc. |
Method for delivery across the blood brain barrier
|
|
WO2008043024A2
(en)
|
2006-10-04 |
2008-04-10 |
Kalypsys, Inc. |
Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
|
|
WO2008073918A1
(en)
|
2006-12-11 |
2008-06-19 |
Kempharm, Inc. |
Non-standard amino acid conjugates of amphetamine and processes for making and using the same
|
|
DE102007004781A1
(de)
|
2007-01-31 |
2008-08-07 |
Alzchem Trostberg Gmbh |
Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
|
|
AU2008213643A1
(en)
|
2007-02-08 |
2008-08-14 |
Kempharm, Inc. |
Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
|
|
WO2009033130A1
(en)
|
2007-09-07 |
2009-03-12 |
Gencia Corporation |
Mitochondrial compositions and uses thereof
|
|
WO2009098142A1
(en)
|
2008-02-06 |
2009-08-13 |
Helm Ag |
Prasugrel salts with improved properties
|
|
EP2198838B1
(fr)
|
2008-12-19 |
2018-09-05 |
L'Oréal |
Procédé et dispositif d'éclaircissement ou de coloration directe éclaircissante ou d'oxydation des fibres kératiniques en présence d'une composition aqueuse riche en corps gras
|
|
FR2940104B1
(fr)
|
2008-12-19 |
2011-08-19 |
Oreal |
Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une composition contenant un agent alcalin
|
|
FR2940077B1
(fr)
|
2008-12-19 |
2012-07-20 |
Oreal |
Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une composition anhydre colorante comprenant un agent alcalin et une composition oxydante.
|
|
JP5866137B2
(ja)
|
2009-04-30 |
2016-02-17 |
ロレアル |
アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン化合物を含む組成物を用いたヒトケラチン繊維の明色化および／または着色ならびに装置
|
|
WO2011033068A1
(en)
|
2009-09-18 |
2011-03-24 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
|
MX2012004036A
(es)
|
2009-10-09 |
2012-06-27 |
Achaogen Inc |
Analogos de aminoglicosidos antibacterianos.
|
|
US8173181B2
(en)
|
2009-11-09 |
2012-05-08 |
Bio-Engineered Supplements & Nutrition, Inc. |
Method and composition for improved anabolism
|
|
FR2954160B1
(fr)
|
2009-12-22 |
2012-03-30 |
Oreal |
Composition de coloration ou d'eclaircissement comprenant un corps gras et un polymere amphotere
|
|
US8715699B2
(en)
|
2009-12-31 |
2014-05-06 |
Kempharm, Inc. |
Amino acid conjugates of quetiapine, process for making and using the same
|
|
DE102010012199A1
(de)
|
2010-03-19 |
2011-09-22 |
Fresenius Medical Care Deutschland Gmbh |
Molekular geprägte Polymere für die Eliminierung von Metaboliten
|
|
FR2958161B1
(fr)
|
2010-04-02 |
2012-04-27 |
Oreal |
Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin
|
|
EP3540059A1
(en)
|
2010-04-16 |
2019-09-18 |
Nuevolution A/S |
Bi-functional complexes and methods for making and using such complexes
|
|
US20110262359A1
(en)
|
2010-04-21 |
2011-10-27 |
Jenkins Thomas E |
Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
|
|
EP2560490A1
(en)
|
2010-04-21 |
2013-02-27 |
Signature Therapeutics, Inc. |
Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
|
|
US20130059914A1
(en)
|
2010-04-21 |
2013-03-07 |
Signature Therapeutics, Inc. |
Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
|
|
US20110262355A1
(en)
|
2010-04-21 |
2011-10-27 |
Jenkins Thomas E |
Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
|
|
CA2795222A1
(en)
|
2010-04-21 |
2011-10-27 |
Signature Therapeutics, Inc. |
Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
|
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
|
WO2011143534A1
(en)
|
2010-05-13 |
2011-11-17 |
The Mclean Hospital Corporation |
Methods for the treatment of psychiatric disorders
|
|
EP2399885A1
(en)
|
2010-06-22 |
2011-12-28 |
Ulrich Dietz |
Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification
|
|
WO2012024611A1
(en)
|
2010-08-20 |
2012-02-23 |
Natural Alternatives International, Inc. |
Methods of treating sarcopenia and frailty
|
|
WO2012047630A2
(en)
|
2010-09-27 |
2012-04-12 |
Martin Teintze |
N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
|
|
US8765115B2
(en)
|
2010-12-01 |
2014-07-01 |
National Institute of Agrobiological Scienses |
Method of treatment of gastrointestinal disorders with IL-10
|
|
WO2012122412A2
(en)
|
2011-03-09 |
2012-09-13 |
Signature Therapeutics, Inc. |
Compositions for reducing risk of adverse events caused by drug-drug interactions
|
|
WO2012122420A2
(en)
|
2011-03-09 |
2012-09-13 |
Pharmacofore, Inc. |
Opioid prodrugs with heterocyclic linkers
|
|
JP6148182B2
(ja)
|
2011-03-09 |
2017-06-14 |
シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. |
複素環式リンカーを有する活性薬剤プロドラッグ
|
|
WO2012138214A1
(en)
|
2011-04-08 |
2012-10-11 |
Brewster Lizzy Maritza |
Beta-guanidinopropionic acid for the treatment of hypertension
|
|
WO2012173846A2
(en)
|
2011-06-06 |
2012-12-20 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
CN102850242A
(zh)
|
2011-06-27 |
2013-01-02 |
天津天成制药有限公司 |
胍基丙酸硝酸盐的制备方法
|
|
US8427223B2
(en)
|
2011-07-19 |
2013-04-23 |
Lsi Corporation |
Voltage level translator circuit for reducing jitter
|
|
CA3123900A1
(en)
|
2011-07-28 |
2013-01-31 |
Kempharm Inc. |
Methylphenidate-prodrugs, processes of making and using the same
|
|
TW201806968A
(zh)
|
2011-10-18 |
2018-03-01 |
艾利倫治療公司 |
擬肽巨環化合物
|
|
FR2983407B1
(fr)
|
2011-12-06 |
2014-01-03 |
Oreal |
Composition aqueuse riche en huile et son utilisation dans un procede de coloration d'oxydation ou de decoloration
|
|
EP2819688A4
(en)
|
2012-02-15 |
2015-10-28 |
Aileron Therapeutics Inc |
TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
|
|
BR112014020103A2
(pt)
|
2012-02-15 |
2018-10-09 |
Aileron Therapeutics, Inc. |
macrociclos peptidomiméticos
|
|
NZ703341A
(en)
|
2012-06-05 |
2016-11-25 |
Neuroderm Ltd |
Compositions comprising apomorphine and organic acids and uses thereof
|
|
CA2877030A1
(en)
|
2012-06-22 |
2013-12-27 |
Basf Se |
Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
|
|
WO2014071067A2
(en)
*
|
2012-10-31 |
2014-05-08 |
The Rockefeller University |
Treatment and diagnosis of colon cancer
|
|
FR2997846B1
(fr)
|
2012-11-09 |
2023-10-20 |
Oreal |
Composition comprenant un derive dicarbonyle et un acide, le procede de lissage des fibres keratiniques a partir de cette composition
|
|
WO2014138492A1
(en)
|
2013-03-08 |
2014-09-12 |
Solan, LLC |
Methods for fabricating graphite-based structures and devices made therefrom
|
|
CN103288685B
(zh)
|
2013-07-03 |
2015-02-18 |
郭礼强 |
一种3-胍基丙酸的制备方法
|
|
CN104341450B
(zh)
|
2013-08-09 |
2018-03-27 |
北京健峤医药科技有限公司 |
一种磷酸肌酸衍生物的合成与药学应用
|
|
JP2018511645A
(ja)
*
|
2015-04-17 |
2018-04-26 |
ボストン バイオメディカル， インコーポレイテッド |
癌を治療するための方法
|
|
WO2016176636A1
(en)
|
2015-04-30 |
2016-11-03 |
Rgenix, Inc. |
Inhibitors of creatine transport and uses thereof
|
|
US20170056352A1
(en)
*
|
2015-08-25 |
2017-03-02 |
Rgenix, Inc. |
PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
|
|
WO2018160178A1
(en)
*
|
2017-03-01 |
2018-09-07 |
Rgenix, Inc. |
Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
|